


Meet the CML milestones that matter

This is a simplified way to understand chronic myeloid leukemia (CML) treatment milestones. Think of the dots shown in the body as the amount of leukemic cells in the blood, as measured by the presence of the BCR-ABL gene. With each treatment milestone achieved, the amount of leukemia in the body is reduced.



References: 1. Hehlmann, R., et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. *J Clin Oncol*. 10 February 2014; 32(5):415-423. 2. Kantarjian, H.M., et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. *Lancet Oncol*. 18 August 2011; 12:841-851. 3. Kantarjian, H.M., et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). *Blood*. 9 December 2011; 119:1123-1129.